Sensei Biotherapeutics (FTH) to Announce Earnings on Tuesday

Sensei Biotherapeutics (NASDAQ:FTH) is projected to post its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Sensei Biotherapeutics to post earnings of ($5.0450) per share for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:30 AM ET.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. On average, analysts expect Sensei Biotherapeutics to post $-17 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sensei Biotherapeutics Stock Down 3.4%

NASDAQ:FTH traded down $1.00 during mid-day trading on Tuesday, reaching $28.24. 91,205 shares of the stock were exchanged, compared to its average volume of 197,006. Sensei Biotherapeutics has a 1-year low of $6.32 and a 1-year high of $37.90. The firm has a market cap of $37.84 million, a P/E ratio of -0.20 and a beta of -0.26.

Insider Buying and Selling

In other news, CEO Anand Kiran Parikh acquired 2,806 shares of the stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the transaction, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider directly owned 130,142 shares in the company, valued at approximately $2,605,442.84. This trade represents a 16.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders bought 49,494 shares of company stock valued at $1,188,822. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC increased its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:FTH) by 10.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned about 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on FTH shares. Robert W. Baird began coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 price objective on the stock. Loop Capital set a $50.00 target price on shares of Sensei Biotherapeutics in a report on Thursday, May 28th. Weiss Ratings began coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. Citigroup started coverage on Sensei Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $55.00 price objective for the company. Finally, Wall Street Zen lowered Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $54.75.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.